Azitra Inc Common Stock (AZTR)

FairStock Score: 52/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Azitra is not a business in the Graham sense; it is a pre-revenue, clinical-stage biotech with 13 employees. The SEC filings show revenue of $686,000 in fiscal year 2023 (period ended 2023-12-31), just $7,500 in fiscal year 2024 (period ended 2024-12-31), and revenue N/A in fiscal year 2025 (period ended 2025-12-31). Net losses were $11.3M in fiscal year 2023 (period ended 2023-12-31), $9.0M in fiscal year 2024 (period ended 2024-12-31), and $11.0M in fiscal year 2025 (period ended 2025-12-31). In the quarter ended 2026-06-30, net loss was $3.3M, and diluted EPS was $-0.17; in the quarter ended 2026-03-31, net loss was $3.9M and diluted EPS $-0.25. That is not an earnings record; it is a cash-consuming research effort. FairStock calculations tied to the 2026-10-13 close show P/B 0.60, ROE -256.67%, ROCE -119.91%, Piotroski 1/9, and Altman Z -9.45. Free cash flow is $-11.4M TTM, a FCF yield of -260.9% versus a $4.4M market cap. The low D/E of 0.06 is a small comfort, but no revenue and heavy losses make the capital structure fragile. The FairStock P/E of 3.60 conflicts with the filed losses, so I would not treat the stock as statistically cheap. The Graham Number of $0.45 and 84% margin of safety are mechanical outputs, not proof of value. Competitive moat? None visible; the only potential asset is clinical data, which is binary and years away. The Lynch category is none because the company lost money in each of the last four years. I prefer businesses that earn money now. Azitra is a speculation on future trial success, not an investment with a margin of safety in my view.

In plain English: Azitra is a tiny early-stage drug company working on skin treatments. It has almost no revenue, loses money each year, and burns cash, so the business looks weak. At seven cents, the stock may look cheap against some calculated numbers, but with no profits and ongoing losses it is hard to call it a bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer